Bottomley A., Thomas R., van Steen K. (2002) Human recombinant erythropoietin and quality of life: A wonder drug or something to wonder about?. Lancet Oncol 3:145-153.
Littlewood T.J., Cella D., Nortier J.W.R. (2002) Erythropoietin improves quality of life. Lancet Oncol 3:459-460.
De Bellefeuille C., Morrison C.A., Tannock I.F. (1992) The fate of abstracts submitted to a cancer meeting: Factors which influence presentation and subsequent publication. Ann. Oncol 3:187-191.
Sacks H., Chalmers T.C., Smith H. Jr. (1982) Randomized versus historical controls for clinical trials. Am. J. Med 72:233-240.
Chalmers T.C., Celano P., Sacks H.S., Smith H. Jr. (1983) Bias in treatment assignment in controlled clinical trials. N. Engl. J. Med 309:1358-1361.
Schulz K.F., Chalmers I., Hayes R.J., Altman D.G. (1995) Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412.
Dickersin K., Min Y.I. (1993) NIH clinical trials and publication bias. Online J. Curr. Clin. Trials, [serial online] Document No 50; .
Krzyzanowska M., Pintilie M., Tannock I. (2002) Burying of unwanted results: A survey of more than 500 large randomized clinical trials presented at ASCO meetings to determine the probability and causes of failure to publish. Proc. Am. Soc. Clin. Oncol , (abstr 973); 21.
Hopewell S., Clarke M. (2001) Methodologists and their methods. Do methodologists write up their conference presentations or is it just 15 minutes of fame?. Int. J. Technol. Assess Health Care 17:601-603.
